Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01080807 · ClinicalTrials.gov registry record · Phase 4
Efficacy and Tolerability of Armodafinil in Adults With Excessive Sleepiness Associated With Shift Work Disorder
A Phase 4 study, sponsored by Cephalon.
- Completed
- Registry status
- Phase 4
- Development phase
- 385
- Enrollment target
NCT01080807 is a Phase 4 study that has completed, run by Cephalon. The registered enrollment target is 385 participants.
The verdict
NCT01080807, a Phase 4 study, has completed, sponsored by Cephalon.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 385 participants
- Enrollment target
Study Summary
The primary objective of the study is to determine whether armodafinil treatment is more effective than placebo treatment in patients with excessive sleepiness associated with shift work disorder (SWD) by measuring improved clinical condition late in the shift, including the commute home.
Interventions
- DRUG Matching Placebo
- DRUG Armodafinil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 385 participants |
| Start Date | 2010-03 |
| Est. Completion | 2010-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01080807
The ClinicalTrials.gov registry entry for NCT01080807 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 385 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cephalon, which has 64 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Matching Placebo is the first listed.
NCT01080807 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01080807 about?
NCT01080807 is a clinical study titled "Efficacy and Tolerability of Armodafinil in Adults With Excessive Sleepiness Associated With Shift Work Disorder". The primary objective of the study is to determine whether armodafinil treatment is more effective than placebo treatment in patients with excessive sleepiness associated with shift work disorder (SWD) by measuring improved clinical condition late in the shift, including the commute home.
What is the current status of trial NCT01080807?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 385 participants. The study started on 2010-03. Estimated completion is 2010-10.
What interventions are being tested in trial NCT01080807?
The interventions under investigation include: Matching Placebo (DRUG), Armodafinil (DRUG).
Who is sponsoring clinical trial NCT01080807?
This trial is sponsored by Cephalon, which has 64 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.